The Dengue virus (DENV) envelope (E) protein is the major component of the viral surface and is structurally subdivided into three domains, ED1, ED2 and ED3. ED3 elicits potent neutralizing antibodies and contains two major antigenic sites: the DENV-type-specific and DENV-complex-reactive antigenic sites. Each site is composed of a limited subset of residues that are required for monoclonal antibody (mAb) binding. Here we show that DENV-2-type-specific mAb 9A3D-8 utilizes the functionally critical residues K307, V308, K310, I312, P332, L387, L389 and N390 for ED3 binding. Surprisingly, this DENVtype-specific epitope is predicted to overlap with the ED3 DENV-complex-reactive antigenic site on the viral surface. Further, this unique binding site enables mAb 9A3D-8 to neutralize virus infectivity at relatively low occupancy of virions compared to other ED3 mAbs identified to date. Together, the data in this study indicate that this is a new DENV-2-type-specific antigenic site on ED3.
The four Dengue viruses (DENVs) are mosquito-borne viruses belonging to the genus Flavivirus. The DENV virion is an enveloped icosahedron with a positive-sense RNA genome that codes for a single polyprotein that is co-and post-translationally processed into 10 distinct proteins. The envelope (E) protein is the major component of the viral surface, with 180 copies arranged as 90 anti-parallel homodimers. Each E protein ectodomain is structurally subdivided into the central E protein domain I (ED1), the dimerization domain with the fusion loop (ED2) and the putative receptor-binding domain (ED3) [1] . Furthermore, the E protein is the primary antigen targeted by the humoral immune response [2] . Specifically, the majority of antibodies target ED2, and ED3 elicits potent neutralization antibodies [3, 4] .
Antibody mapping and E protein structural analyses led to the identification of several epitopes on the E protein.
Monoclonal antibodies (mAbs) that only recognize one DENV serotype are termed type-specific, whereas mAbs that recognize all four serotypes are termed DENVcomplex-reactive (Table S1 , available in the online Supplementary Material). Two major antigenic sites were mapped to the DENV-2 ED3: the DENV-2-type-specific and DENV-complex-reactive antigenic sites, which are composed of a limited subset of residues that are required for mAb binding [4] [5] [6] [7] . ED3 amino acid substitutions that strongly affect the binding of mAbs are termed critical residues, and those that have a moderate effect on mAb binding to ED3 are termed peripheral residues. The DENV-2-typespecific antigenic site is located on the ED3 lateral ridge, including the F-G loop, and extends partially into the Astrand; amino acid residues K305 and P384 are critical for mAb binding and E327, E329, P332 and E383 are peripheral epitope residues (Fig. S1 ). The DENV-complex-reactive antigenic site occupies the opposite end of the A-strand, the G-strand, and part of the F-G loop. It has one critical residue, K310, and the peripheral residues K307, I312, P332, P384, L387, L389 and W391 [5] [6] [7] [8] [9] . Therefore, the two antigenic sites partially overlap. Further, evidence shows that both mouse and primate anti-DENV antibodies target the E protein. Studies of dengue-infected human serum samples (from several geographic locations) with wild-type (WT) or mutant-virus-like particles show that DENV-2-specific ED3 antibodies are positively and significantly correlated with neutralization [2] . Although the proportion of these antibodies is small, the data indicate that potent antibody epitopes in mice play a role in human antibody neutralization of DENV-2. Furthermore, epitopes of neutralizing human mAbs (hmAbs) and mouse mAbs can partially overlap. Epitopes of the DENV-2 ED3-reactive hmAbs DV3.7 and DV10.16 include amino acids in the lateral ridge (V382 and P384) and in the A-strand (K305, K310, and E311), respectively [10, 11] . Therefore, epitopes of hmAbs contain some amino acids composing the DENV-2 antigenic sites.
Mouse mAb 9A3D-8 is a DENV-2-type-specific mAb. Initial epitope characterizations indicated that mAb 9A3D-8 competed with both DENV-2-type-specific (3H5) and DENV-complex-reactive (10A4D-2) mAbs for binding and recognized the same proteolytic fragment as DENVcomplex-reactive mAb 1A1D-2 [4] . A subsequent study using random recombinant ED3 (rED3) mutants displayed on yeast to screen mAb 9A3D-8 [6] resulted in the identification of K307, a residue that is critical for the binding of DENV-complex-reactive mAbs such as mAb 1A1D-2 [8, 12] . Further, a triple substitution infectious clone mutant of the three lysines in the A-strand, KKK305/307/310EEE, was used to show that these residues affect mAb 9A3D-8 binding [4, 13] . Thus, there is evidence that the apparent DENV-2-type-specific mAb 9A3D-8 may share a binding site with DENV-complex-reactive mAbs. In order to further dissect the unique target of mAb 9A3D-8, both the binding and neutralization activity of mAb 9A3D-8 were examined in this study.
Single-site substitution mutants of rED3 were utilized to map the binding of the DENV-2-type-specific mAb 9A3D-8, as described previously [5, 7] . Briefly, this strategy has been used to substitute the surface-exposed residues of ED3 with a glycine or alanine (to remove the side chain), or with a naturally occurring substitution found in genetically related DENV-2 strains [14] . The apparent affinity of mAb 9A3D-8 to WT rED3 [based on the Asian II genotype strain New Guinea C (NGC)] and to 37 mutant rED3s was determined in ELISAs. The individual dissociation constants (K D ) were expressed relative to the affinity of mAb to WT rED3 (Fig. 1a) . Further, relative K D values were used to describe the effect of each substitution on 9A3D-8 binding as: weak (0 to four fold increase in affinity), moderate (fourto 10-fold), or strong/critical (10-fold). A side-by-side comparison with the well-characterized mAbs 3H5 (DENV-2-type-specific) and 1A1D-2 (DENV-complex-reactive) was performed ( Fig. 1) [5, 6, 8, 9] .
Similarly to previously characterized DENV-2 ED3-specific mAbs, the majority of residues on the surface of ED3 were not involved in the interaction between rED3 and mAb 9A3D-8, resulting in weak changes to mAb affinity (Fig. 1) . The residues that were critical for mAb 9A3D-8 binding were primarily located in the A-strand (K307, V308, K310 and I312) and the G-strand (L387, L389 and N390). Topologically, all of these residues are in close proximity to each other (Fig. 1b) . The binding of mAb 9A3D-8 was also strongly affected by P332 in the B-C loop. Interestingly, P332 has been hypothesized to act through long-range communication because it is not located near the critical residues that compose both the DENV-2-type-specific and DENV-complex-reactive antigenic sites [5, 7, 15] . Overall, the mAb 9A3D-8 binding site shares four critical residues with the DENV-complex-reactive mAb 1A1D-2 (K307, K310, I312 and P332), but only one with DENV-2-typespecific mAb 3H5 (V308).
Next, a comparison of the peripheral residues showed that mAbs 9A3D-8 and 1A1D-2 shared E311 and P384 as peripheral residues, and that L387 and L389 were both critical for 9A3D-8 but peripheral for 1A1D-2 binding. Further, mAb 3H5 and mAb 9A3D-8 shared E327, E338, K344 and E383 as peripheral residues (Fig. 1b) . In summary, the DENV-2-type-specific mAb 9A3D-8 antigenic site had more critical residues in common with the antigenic site of the DENV-complex-reactive mAb 1A1D-2 than with that of DENV-2-type-specific mAb 3H5 (Table S2 ). Therefore, 9A3D-8 is a DENV-2-type-specific mAb that binds to the DENV-complex-reactive antigenic site.
The mAb 9A3D-8 epitope spans across ED3 and, by requiring both K310 and P384, encompasses both DENV-2-type-specific and DENV-complex-reactive antigenic sites. Typical DENV-2-type-specific-mAbs bound epitopes centred on K305 in the A-strand and P384 in the F-G loop [5, 6] . Conversely, DENV-complex-reactive-mAbs bound epitopes centred on K310 in the A-strand, on the opposite side of ED3 [6, 7] . The critical residues determined using rED3 demonstrated that mAb 9A3D-8 required the DENVcomplex-reactive critical residues (K307, K310 and I312F) in the A-strand. Further, these assays showed that the DENV-2-type-specific critical residues were required for binding, albeit to a lower level (peripheral). Specifically, of the DENV-2-type-specific critical residues, the substitution P384A resulted in the largest change in mAb affinity (8.1-fold), but at less than 10-fold was classified as a peripheral residue for binding. Furthermore, the biological mapping of P384 using DENV-2-infectious-clone-derived mutants demonstrated that this residue was functionally important for neutralization [6, 9] . Taken together, these results demonstrate that mapping studies with rED3 can identify important antibody-binding and functional (for biological neutralization) residues, but peripheral residues with reduced affinity near to 10-fold should be carefully considered and may be critical residues. Further analysis is required to determine if the DENV-2-type-specific critical residues are contact residues for mAb 9A3D-8 or exhibit their effects through long-range communication [15] .
The effects of the DENV-2-type-specific critical residues on viral neutralization by mAb 9A3D-8 were examined. DENV-2 16 681 infectious clones (ICs) engineered with DENV-2-type-specific critical residue substitutions of K305A or P384A (with G330D) were used in neutralization tests [9] . [Previous IC studies found that substitutions or deletions in the F-G loop (381-386) led to compensatory mutations; therefore, the P384A substitution was only recovered with the additional G330D.] DENV-2 strain NGC was used as a control WT strain. Each virus was incubated with saturating concentrations of mAbs 3H5 or GTX29202, or with saturating dilutions of 9A3D-8 and 4G2 ascitic fluid prior to the infection of African green monkey Vero cells. Both DENV-2-type-specific mAbs 9A3D-8 and 3H5 exhibited similar activities by neutralizing all viruses with WT ED3 sequences [strains NGC and 16 681 WT IC (Fig. 2a) ] and the K305A IC-derived mutant, but they could only neutralize approximately 50 % infectivity of the P384A+G330D IC-derived mutant (Fig. 2a) . This is in accordance with previous results showing that maximal neutralization of P384A+G330D IC by mAb 3H5 only reached 50-60 % neutralization, which required 70-fold more antibody than was required to neutralize WT virus [9] . In contrast, the DENV-complex-reactive mAb GTX29202 and the flavivirus group-reactive mAb 4G2 (which binds ED2) neutralized all four viruses. These results demonstrated that substitution of P384A affected the neutralizing efficacy of mAb 9A3D-8. It is possible that there is a synergistic effect of P384A and G330D in neutralization of the mutant virus; however, the epitope mapping showed that G330D did not affect binding. Taken together with the ELISA mapping data, these results indicate that mAb 9A3D-8 binds to both the DENV-2-type-specific and DENV-complex-reactive antigenic sites.
To determine the relationship between mAb neutralization and occupancy on the virus, mAb 9A3D-8 was used in 50 % focus-reduction-neutralization-titre (FRNT 50 ) assays and virus-capture ELISAs of purified NGC. Neutralization of DENV-2 NGC by DENV-2-type-specific mAbs 3H5 and 9A3D-8 was similar (FRNT 50 1.1 and 0.88 nM, respectively), whereas approximately five fold more DENV-complexreactive mAb MDVP-55A was required to neutralize the virus (Fig. 2b) . Next, virus-capture ELISAs were performed with mAb 9A3D-8 and a panel of additional mAbs, as described previously [7] . The results revealed an apparent affinity of 1.7±0.6 nM (data not shown) for mAb 9A3D-8, which is comparable to that for other DENV-2-type-specific mAbs (K D approximately 0.9-4.3 nM); however, it differs significantly from the affinities of the DENV-complexreactive mAbs (K D 0.13-0.43 nM [P<0.05]) [5, 7] .
The affinity values from the ELISAs were used to calculate the predicted mAb occupancies, as previously performed [16, 17] . The DENV-2-type-specific mAbs 3H5 and 5C36 exhibited a linear relationship between occupancy and neutralization (Fig. 2c) . In contrast, the DENV-complexreactive mAbs apparently have an exponential relationship, which may be explained by a difference in the threshold to achieve detectable neutralization (Fig. 2c, d) . Interestingly, mAb 9A3D-8 exhibits a unique sigmoidal relationship (best fitted by the four-parameter logistic equation with a variable slope) between occupancy and neutralization (Fig. 2c) . The average occupancies required for each mAb to neutralize 10, 50 and 90 % infectivity, respectively, were compared (Fig. 2d) . The DENV-2-type-specific mAbs require the lowest mAb occupancy to neutralize 10 % infectivity, followed by mAb 9A3D-8, and the DENV-complex-reactive mAbs, with mean occupancies of 11, 20 and 72 %, respectively. However, mAb 9A3D-8 required the lowest mAb occupancy (35 %) to neutralize 50 % infectivity, followed by the DENV-2-type-specific and DENV-complex-reactive mAbs, with 52 and 91 %, respectively. Overall these data show that mAb 9A3D-8 requires higher occupancy than other DENV-2-type-specific mAbs to achieve low levels of neutralization, but maximum neutralization is reached with lower occupancy. This suggests that mAb 9A3D-8 functions within a narrow occupancy range, which could be explained by the fact that 9A3D-8 has a broader epitope that occupies a larger area on the viral surface (Fig. 3) .
MAb 9A3D-8 may neutralize virus infectivity by a similar mechanism to the DENV-complex-reactive mAbs. This hypothesis is supported by Crill and Roehrig, who demonstrated that mAb 9A3D-8 neutralized by blocking viral infection, similarly to the DENV-complex-reactive mAb 1A1D-2, and that it blocked to a greater extent than the DENV-2-typespecific mAb 3H5 (42 and 36% blocking, respectively) [18] .
The epitope mapping study by Sukupolvi-Petty and colleagues demonstrated that 9A3D-8 required G304, K307 and E327 to bind to rED3 displayed on yeast. Their results differ from the epitope determined in the present study, as only K307 was identified in both. This may be due to the difference in methodology, as the former involved random mutagenesis of rED3 displayed on yeast to determine if mutations resulted in loss of mAb binding at an unspecified concentration [6] , whereas this study used site-directed mutagenesis of rED3 in ELISAs and serial mAb dilutions to calculate the apparent K D . Unlike the study by Sukupolvi-Petty and colleagues, none of the critical residue substitutions resulted in complete loss of binding, but they significantly affected the apparent affinity of mAb 9A3D-8 for rED3.
The DENV-complex-reactive mAb 1A1D-2 binds to ED3 in the three-and five fold axes of symmetry on the mature virion, whereas the DENV-2-type-specific mAbs are thought to bind to the two-and three fold axes (in an analogous position to the WNV mAb E16) [8, 19] . Structural modelling of both epitopes on the three fold axis of symmetry is shown in Fig. S2 , but additional studies are needed to correlate the neutralization mechanism with symmetry sites on the virion. Furthermore, structural analyses show that the DENV-complex-reactive critical residue K310 interacts with the ED2 W101 located on the fusion loop of the opposite subunit. Docking analysis of the DENV-complex-reactive mAb 4E11 with ED3 onto E dimers showed disruption of the contacts, which may lead to dissociation of dimers and the structural integrity of the E protein [20] .
Typically, DENV-2-type-specific mAbs are isotype IgG1 and exhibit higher neutralization potency, whereas the DENVcomplex-reactive mAbs are IgG2a and are less potent [14] . Because mAb 9A3D-8 is IgG2a and spans across both type- specific and complex-reactive epitopes, it is possible that the isotype or sub-class may play a role in virus binding and neutralization. Future structural studies may provide insights into how mAb 9A3D-8 recognizes its epitope.
In conclusion, these results demonstrate that mAb 9A3D-8 binds to a unique epitope that spans the DENV-2-type-specific and DENV-complex-reactive antigenic sites on ED3. Comparison of the relationship between mAb occupancy and neutralization revealed a sigmoidal relationship. mAb 9A3D-8 likely represents a different class of DENV-2-typespecific ED3 mAb. Further analysis is required to determine which symmetry sites mAb 9A3D-8 binds and what mechanism is used to neutralize virus.
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